Proof of rebamipide induced mucosal effect for NSAIDs injuries of small bowel

Proof of rebamipide induced mucosal effect for NSAIDs injuries of small bowel - Treatment of NSAIDs induced small bowel injuries

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006625

Enrollment

Registered

2011-10-28

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSAIDs induced mucosal injuries of small bowel

Interventions

rebamipide placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who diagnosed small intestinal mucosal damages by balloon endoscopy, capsule endoscopy, esophagogastroduodenal endoscopy, and colonoscopy (2)Patients who took NSAIDs and/or low-dose aspirin without bleeding

Exclusion criteria

Exclusion criteria: (1)Patients who need active treatment for small bowel lesion (2)Patients who have hitstory of small bowel disease such as Crohn's disease (3)Patients whose lesions are associated with other factors except NSAIDs (4)Patients who need high-dose streoid therapy (5)Contraindication of capsule endoscopy (6)Patients who have severe liver, renal, and cardiopulmonary dysfunctions, malignant diseases (7)Pregnant patients

Design outcomes

Primary

Measure	Time frame
Capsule endoscopic findings (ulcer, erosion, erythema, bleeding spot, denuded mucosa)	—

Secondary

Measure	Time frame
adverse effect	—

Countries

Japan

Contacts

Public ContactMototsugu KATO

Hokkaido University Hospital Endoscopy

m-kato@med.hokudai.ac.jp+81-11-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026